Propanc biopharma, inc.PPCB.US Overview

US StockHealthcare

(No presentation for PPCB)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

PPCB Overall Performance

PPCB AI Analysis & Strategy

PPCB Recent Performance

-6.76%

Propanc biopharma, inc.

0.81%

Avg of Sector

-1.14%

S&P500

PPCB PowerScanner

PPCB Key Information

PPCB Valuation Metrics

PPCB Earnings Table

PPCB Profile

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.